Cipla This fall FY25 outcomes anticipated to point out 9% revenue development, pushed by India gross sales and respiratory portfolio, regardless of US generic challenges.>
Cipla This fall Earnings Preview: India Drives Progress

Leave a comment
Cipla This fall FY25 outcomes anticipated to point out 9% revenue development, pushed by India gross sales and respiratory portfolio, regardless of US generic challenges.>
Sign in to your account